Looking to understand why some brain tumors with a specific mutation can start to reject drugs commonly used to treat them, CU Cancer Center member Jean Mulcahy Levy, MD, led researchers from institutions around the country—including several from the University of Colorado School of Medicine—to study samples of brain tumors before and after treatment with the drug.